Organization Profile

You just read:

BESPONSA™ Approved by Health Canada for the Treatment of Adults with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

News provided by

Pfizer Canada Inc.

Apr 06, 2018, 15:00 ET